Molecular therapy for Bone disorders: ARIH2 nhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 2/January/2017, 11.00 pm

Small molecule-based PD-1 pathway blockade for Human cancer therapy: HOXA10 inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 2/January/2017, 10.53 pm
January 2, 2017
Natural product-derived combination therapy for augmenting the anti-cancer drug 5-FU (5-Flurouracil) sensitivity in Human cancers: Puerarin, isolated from Cucurbita texana, decreases the expression of the rate-limiting enzyme of the ‘uracil catabolic pathway’ Dihydropyrimidine dehydrogenase (DPYD), increases 5-FU accumulation in cancer cells, augments chemosensitivity, and anti-tumor effect via upregulation of its target gene, 3/January/2017, 11.53 am
January 3, 2017
Show all

Introduction: What they say

A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”

This study was published in the June 25, 2014 Nature  [I.F >42] by Prof. Wan Y, Krzeszinski and others from  the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.


What we say:

On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: ARIH2 inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene


From Research findings to Therapeutic utility

ARIH2, by up-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis. 

price-50[easy_payment currency=”USD”]

Thus, pharmacological formulations encompassing”ARIH2 activators or ARIH2 activator plus compounds that are in use to treat osteoporosis” can be used to inhibit osteoporosis and bone metastasis.


Details of the research findings

Idea Formulated (with experimental evidence) by: Dr L Boominathan PhD

Undisclosed mechanistic information: How ARIH2  suppresses the expression of Tgif2

Amount: $50#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

#Research cooperation

For purchase & payment details, you may reach us at admin@genomediscovery.org


 References:

CitationBoominathan, L., Molecular therapy for Bone disorders: ARIH2 nhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 2/January/2017, 11.00 pm., Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Comments are closed.